NASDAQ:MBIOMustang Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mustang Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.73 +0.16 (+4.48 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$3.52Now: $3.73▼$3.7750-Day Range$2.63MA: $2.91▼$3.7052-Week Range$1.78Now: $3.73▼$4.85Volume483,217 shsAverage Volume470,771 shsMarket Capitalization$159.79 millionP/E RatioN/ADividend YieldN/ABeta1.54 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase I/II clinical trials. The company also develops CD123, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; CD20 for immunotherapy of B-cell lymphomas; CS1, an NK cell receptor regulating immune functions; IL13Ra2 CAR T cell program for glioblastoma; HER2 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; and PSCA CAR T for prostate and pancreatic cancers. It has a license agreement with Harvard University for the treatment of cancer; Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMustang Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Mustang Bio has a potential upside of 141.3% from its current price of $3.73.Amount of Analyst CoverageMustang Bio has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesMustang Bio has received 138 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMustang Bio has received 151 “underperform” votes. (Add your “underperform” vote.)Community SentimentMustang Bio has received 52.25% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote “Outperform” if you believe MBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMustang Bio does not currently pay a dividend.Dividend GrowthMustang Bio does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mustang Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $805,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Mustang Bio is held by insiders.Percentage Held by InstitutionsOnly 20.87% of the stock of Mustang Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mustang Bio are expected to decrease in the coming year, from ($1.04) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mustang Bio is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mustang Bio is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMustang Bio has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.78 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MBIO Previous Symbol CUSIPN/A CIK1680048 Webwww.mustangbio.com Phone781-652-4500Debt Debt-to-Equity Ratio0.28 Current Ratio5.75 Quick Ratio5.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book3.49Profitability EPS (Most Recent Fiscal Year)($1.29) Net Income$-46,390,000.00 Net MarginsN/A Return on Equity-84.09% Return on Assets-61.08%Miscellaneous Employees38 Outstanding Shares42,840,000Market Cap$159.79 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:MBIO Rates by TradingView Receive MBIO News and Ratings via Email Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions How has Mustang Bio's stock been impacted by COVID-19 (Coronavirus)? Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MBIO stock has increased by 58.7% and is now trading at $3.73. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Mustang Bio? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mustang Bio. When is Mustang Bio's next earnings date? Mustang Bio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Mustang Bio. How were Mustang Bio's earnings last quarter? Mustang Bio Inc (NASDAQ:MBIO) posted its earnings results on Monday, May, 11th. The company reported ($0.28) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.03. View Mustang Bio's earnings history. What price target have analysts set for MBIO? 3 equities research analysts have issued 1 year price objectives for Mustang Bio's shares. Their forecasts range from $7.00 to $13.00. On average, they expect Mustang Bio's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 141.3% from the stock's current price. View analysts' price targets for Mustang Bio. Has Mustang Bio been receiving favorable news coverage? News headlines about MBIO stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mustang Bio earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutMustang Bio. Are investors shorting Mustang Bio? Mustang Bio saw a decline in short interest in May. As of May 15th, there was short interest totaling 303,300 shares, a decline of 19.0% from the April 30th total of 374,400 shares. Based on an average daily trading volume, of 253,500 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.1% of the shares of the stock are sold short. View Mustang Bio's Current Options Chain. Who are some of Mustang Bio's key competitors? Some companies that are related to Mustang Bio include Assembly Biosciences (ASMB), Morphic (MORF), ZIOPHARM Oncology (ZIOP), DiaMedica Therapeutics (DMCAF), Stemline Therapeutics (STML), Radius Health (RDUS), Syndax Pharmaceuticals (SNDX), Passage Bio (IMRA), Frequency Therapeutics (FREQ), Athersys (ATHX), Aprea Therapeutics (APRE), Dynavax Technologies (DVAX), Trillium Therapeutics (TRIL), Passage Bio (KROS) and Corbus Pharmaceuticals (CRBP). View all competitors. What other stocks do shareholders of Mustang Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), Protalix Biotherapeutics (PLX), Aduro BioTech (ADRO), Anavex Life Sciences (AVXL), Fortress Biotech (FBIO), Nabriva Therapeutics (NBRV) and Sangamo Therapeutics (SGMO). Who are Mustang Bio's key executives? Mustang Bio's management team includes the following people: Mr. Michael S. Weiss, Exec. Chairman (Age 53)Dr. Manuel Litchman, Pres, CEO & Director (Age 65)Mr. David Jay Horin CPA, Interim Chief Financial Officer (Age 51)Mr. Brian K. Achenbach, VP of Fin. & Corp. Controller (Age 54)Dr. Knut Niss, Chief Technology Officer What is Mustang Bio's stock symbol? Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO." Who are Mustang Bio's major shareholders? Mustang Bio's stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.95%), Ikarian Capital LLC (0.83%), FNY Investment Advisers LLC (0.47%), National Asset Management Inc. (0.39%), Acadian Asset Management LLC (0.31%) and DAVENPORT & Co LLC (0.18%). Company insiders that own Mustang Bio stock include Lindsay A Md Rosenwald and Manuel Md Litchman. View institutional ownership trends for Mustang Bio. Which institutional investors are selling Mustang Bio stock? MBIO stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Mustang Bio. Which institutional investors are buying Mustang Bio stock? MBIO stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, DAVENPORT & Co LLC, Squarepoint Ops LLC, FNY Investment Advisers LLC, Telemetry Investments L.L.C., Los Angeles Capital Management & Equity Research Inc., GSA Capital Partners LLP, and Ikarian Capital LLC. Company insiders that have bought Mustang Bio stock in the last two years include Lindsay A Md Rosenwald, and Manuel Md Litchman. View insider buying and selling activity for Mustang Bio. How do I buy shares of Mustang Bio? Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mustang Bio's stock price today? One share of MBIO stock can currently be purchased for approximately $3.73. How big of a company is Mustang Bio? Mustang Bio has a market capitalization of $159.79 million. The company earns $-46,390,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Mustang Bio employs 38 workers across the globe. What is Mustang Bio's official website? The official website for Mustang Bio is www.mustangbio.com. How can I contact Mustang Bio? Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at 781-652-4500 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
